Studies related to Interleukin 6 and Coenzyme Q10

Oral Coenzyme Q10 Supplementation In Patients With Migraine: Effects On Clinical Features And Inflammatory Markers

Effect Decrease
Values (ng/L). Mean and SD. Placebo: before 13.54 ± 7.24, after 13.43 ± 7.59. Intervention: before 16.56 ± 9.82, after 15.56 ± 10.31.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 45
Sex Female
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 45 premenopausal women with episodic migraine were allocated to take 400 mg of coq10 daily or placebo for 3 months.

Migraine frequency, severity, and duration were all reduced significantly more than placebo. Calcitonin gene-related peptide and tumor necrosis factor were reduced significantly more in the coq10 group, while IL-6 was reduced nonsignificantly more, and IL-10 increased nonsignificantly more.

Full details on all 6 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.